Evaluation of Lymphedema Patients Status During Covid-19 Pandemic
2020年10月5日 更新者:Fatih Sultan Mehmet Training and Research Hospital
Evaluation of Lymphedema Patients Treatment Processes, Health Status, Coronavirus Phobia, Quality of Life, Anxiety and Depression During Covid-19 Pandemic
The pandemic, which started in China at the end of 2019, appeared in our country in a short time.
Most hospitals and physicians were only concerned with the treatment of these patients.
One of the most victimized patient groups in this duration was lymphedema patients who were in need of continuous follow-up and rehabilitation at necessary periods, but were also at risk in terms of covid-19 infection and could not go to hospitals unless necessary.
The treatment of both primary and secondary lymphedema patients has been interrupted or delayed.
This process has affected the health status, treatment processes and quality of life of the lymphedema patient group.
The current situation may have caused them anxiety and depression as a result of infection fear.
In this study, we aimed to evaluate the treatment processes, health status, coronavirus phobia, anxiety, and depression states of the lymphedema patients .
調査の概要
状態
完了
条件
詳細な説明
60 primary and secondary lymphedema male and female patients with stage I,II,III lymphedema older than 18 years old over who were followed up in the lymphedema outpatient clinic of the Physical Medicine and Rehabilitation Clinic were included in the study.They were called by phone.
Permission was asked for questioning from the patients reached.
A hundred lymphedema patients were called and 60 patients were reached or agreed to be interviewed.
The questions on the form and scales were read clearly to the patients who accepted the interview and were asked to be answered by the patient.
The health status of the admitted patients during the covid-19 pandemic period and the treatment processes were questioned with the form we prepared.These forms were included socio-demographic features, physical, and detailed medical histories.Edema staging was evaluated by the International Society of Lymphology (ISL) lymphedema staging classification.This information was filled in from patients' files.
The pandemic process was evaluated in the other part of the form.
Working status, mobilization during the pandemic process, whether he/she or his/her relative was diagnosed with coronavirus infection, whether he/she received suplemental treatment, how much he/she paid attention to hand-foot hygine, whether his/her swelling increased, whether he/she had a cellulite attack, whether he/she regular self-manual lymphatic drainage and/or exercise, It was questioned whether there was an increase in a different symptom other than swelling, eating habits and weight gain, most recently whether he used pressure stocking regularly.In addition, the fear because of the covid-19 virus was questioned with the coronavirus-19 phobia scale (CP19-S), quality of life with lymphedema quality of life arm / leg (LYMQOL), and anxiety and depression with the hospital anxiety and depression scale (HADS).
研究の種類
観察的
入学 (実際)
60
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Ataşehir
-
Istanbul、Ataşehir、七面鳥、34752
- Fatih Sultan Mehmet Training and Research Hospital
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
サンプリング方法
非確率サンプル
調査対象母集団
Primary or secondary lymphedema patients who aged over 18.
説明
Inclusion Criteria:
- Primary or secondary lymphedema patients with stage I,II,II stage
- Aged over 18 years old
- Upper or lower extremity lymphedema
Exclusion Criteria:
- Patients under the age of 18
- Patients who do not accept phone calls.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:他の
- 時間の展望:断面図
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Coronavirus Phobia Scale
時間枠:1 day
|
The CP19-S has 20 items which is a self-report instrument with a five-point Likert-type scale to assess the levels of coronavirus (covid-19) phobia.
All items are rated on a 5 point scale from "strongly disagree (1)" to "strongly agree (5)."
The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales (psychological, psycho-somatic, economic and social) and total scale.
In the present study total scale scores ranged from 20 to 100 .
|
1 day
|
|
Lymphedema Quality of Life Arm
時間枠:1 day
|
The LYMQOL-Arm consists of four domains with 28 items.
These domains are symptoms, appearance, function, and mood.
The answers were evaluated on a four-point Likert scale (1= not at all 2= a little, 3= quite a bit, 4= a lot).
Each item received a score between 1 and 4, with higher scores indicating a worse QOL.
Domain totals were calculated by adding the individual scores and dividing the total by the number of questions answered (If >50% of questions per domain were not answered this cannot be calculated *and =0).
If the item was not scored and left blank or not applicable, this was scored with a 0. The four domains and their corresponding questions are: Function 1 (a-h), 2,3, Appearance 4,5,6,7,8 Symptoms 9,10,11,12,13,14 and Emotion 15,16,17,18,19,20.
Overall QOL (Q21) is scored as the value marked by the patient, between 0-10
|
1 day
|
|
Lymphedema Quality of Life Leg
時間枠:1 day
|
The LYMQOL-Leg consists of 27 items: 26 multiple-choice questions and 1 rating question.
It covers four domains: symptoms, appearance, function, and mood.
Scoring and calculating is same with the arm scale but differences are; function 1 (a-f), 2,3 appearance 4,5,6,7,8,9,10 symptoms 11,12,13,14,15 and emotion 16,17,18,19,20,21.
Overall quality of life (Q22) is scored as the value marked by the patient, between 0-10.
|
1 day
|
|
Hospital Anxiety and Depression Scale
時間枠:1 day
|
It consists of 14 items with two subscales (seven items for anxiety and seven items for depression).
Each item is scored 0-3.
Each subscale is scored between 0 and 21.
The aim of the scale is not to make a diagnosis, but to determine the risk group bt screening anxiety and depression in a short time in patients with physical diseases.
The cut-off points of the Turkish version of the HADS were determined as 10 for the anxiety subscale and 7 for the depression subscale.
|
1 day
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者:Feyza Akan Begoğlu, MD、Fatih Sultan Mehmet Training and Research Hospital
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2020年6月1日
一次修了 (実際)
2020年8月1日
研究の完了 (実際)
2020年8月1日
試験登録日
最初に提出
2020年9月25日
QC基準を満たした最初の提出物
2020年9月25日
最初の投稿 (実際)
2020年9月29日
学習記録の更新
投稿された最後の更新 (実際)
2020年10月8日
QC基準を満たした最後の更新が送信されました
2020年10月5日
最終確認日
2020年10月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- feyzaakanbegoglu
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。